Deakin University
Browse
- No file added yet -

A new era in the treatment of multiple sclerosis

Download (1.67 MB)
Version 2 2024-06-06, 10:20
Version 1 2016-01-05, 14:55
journal contribution
posted on 2024-06-06, 10:20 authored by SA Broadley, MH Barnett, M Boggild, BJ Brew, H Butzkueven, R Heard, S Hodgkinson, AG Kermode, J Lechner-Scott, RA Macdonell, M Marriott, DF Mason, J Parratt, SW Reddel, Cameron ShawCameron Shaw, M Slee, JM Spies, BV Taylor, WM Carroll, TJ Kilpatrick, J King, PA McCombe, JD Pollard, E Willoughby
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.

History

Journal

Medical journal of Australia

Volume

203

Pagination

139-141

Location

Sydney, N.S.W.

Open access

  • Yes

eISSN

1326-5377

Language

eng

Publication classification

C Journal article, C1 Refereed article in a scholarly journal

Copyright notice

2015, Australasian Medical Publishing

Issue

3

Publisher

Australasian Medical Publishing

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC